David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer


David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.

David M. O’Malley, MD, director of the Division of Gynecologic Oncology at the Ohio State University Comprehensive Cancer Center-The James and professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, spoke with CancerNetwork® about where treatment efforts for patients with endometrial cancer, specifically those with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease, are being focused.


The next steps are so exciting. We have multiple first-line trials in metastatic and recurrent therapies as well as locoregional disease, meaning disease that has been completely removed and has a positive lymph node. We also have a trial which is looking at patients with early-stage disease who are at intermediate risk of recurrence and combining pembrolizumab [Keytruda] with radiation. In addition, maybe one of the most exciting options that we will consider is in patients who have dMMR deficient or MSI-H [disease. Treating those] patients with pembrolizumab vs the standard therapy of carboplatin plus paclitaxel, we may be replacing the cytotoxic agents with a single immune therapy. The future is bright for our patients with uterine cancer, thanks to immune therapies.

Related Videos
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content